Eloxx Pharmaceuticals Inc (NASDAQ:ELOX)

0.286
Delayed Data
As of 3:21pm ET
 -0.0394 / -12.11%
Today’s Change
0.21
Today|||52-Week Range
1.89
-59.50%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$25.6M

Company Description

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins. It operates through the United States and Israel geographical segments. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Watertown, MA.

Contact Information

Eloxx Pharmaceuticals, Inc.
480 Arsenal Way
Watertown Massachusetts 02451
P:(781) 577-5300
Investor Relations:
(203) 274-2825

Employees

Shareholders

Mutual fund holders4.74%
Individual stakeholders32.30%
Other institutional11.61%

Top Executives

Sumit AggarwalPresident, Chief Executive Officer & Director
Daniel E. GeffkenChief Financial & Accounting Officer
Vijay ModurHead-Research & Development
Ali HaririChief Medical Officer
Barbara RyanInvestor Relations Contact